Value proposition

Improving R&D of first-in-human drug candidates in pharma. Supercharging clinical trials. Elevating the quality of care.

RetinAI is a Swiss & US-based software company improving and supporting R&D of first-in-human drug candidates, supercharging management and oversight of clinical trials and enabling the research needed to elevate the quality of care on patients with eye diseases.

We achieve this goal by building tools to collect, analyze and to organize health data. Our fundamental belief is that in the future every patient will use drugs alongside a digital application that will enable them and their physicians to better assess the right drug, in the right amount and the right frequency for patients.



medical image analysis, artificial intelligence, machine learning, med-tech, ophthalmology, optical coherence tomography, Fundus Image Photography, Retinal Angiography, age-related macular degeneration, diabetic retinopathy, glaucoma, Multiple Sclerosis, alzheimer, parkinson, and digital health